Drug Profile
MB 28767
Alternative Names: M&B 28767Latest Information Update: 17 Nov 2003
Price :
$50
*
At a glance
- Originator Nonindustrial source; Nonindustrial sources
- Developer Nonindustrial source
- Class Anti-ischaemics
- Mechanism of Action Prostaglandin agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Reperfusion injury
Most Recent Events
- 17 Nov 2003 Discontinued - Preclinical for Reperfusion injury in Germany (unspecified route)
- 04 Dec 1998 Preclinical development for Reperfusion injury in Germany (Unknown route)
- 04 Dec 1998 Preclinical development for Reperfusion injury in United Kingdom (Unknown route)